|
KMID : 1177220080110020097
|
|
Korean Journal of Schizophrenia Research
2008 Volume.11 No. 2 p.97 ~ p.106
|
|
|
Clinical Guideline for Ziprasidone Use
|
|
Lee Seung-Hwan
Joo Yeon-Ho
Hong Kyung-Sue
Kim Chan-Hyung
kwon Jun-Soo
Kim Jae-Jin
Lee Jung-Seo
Kang Ung-Gu
|
|
|
Abstract
|
|
|
|
Ziprasidone is an atypical antipsychotic agent having an antagonistic effect on dopaminergic receptor (D2) and type2 serotonergic receptor (5HT2). It has shown excellent efficacy against positive and negative symptoms of schizophrenia and better side effect profiles compared to other atypical antipsychotics (i.e., lower metabolic syndrome rate, lower extrapyramidal symptoms rate, and less somnolence, etc.). This article presents clinical guidelines for using ziprasidone focusing on four subtopics, i.e., ‘initiation and titration’, ‘drug switch’, ‘drug compliance’, and ‘identifying the high priority patient’. The recommendations are based on clinical literatures, expert consensus suggestions developed in Canada and Australia, Zeldox Consumer Medical Information, and clinical experiences of the authors. Much more controlled and naturalistic clinical studies on ziprasidone use should be accumulated to develop more evidence-based and comprehensive version of clinical guidelines.
|
|
|
KEYWORD
|
|
|
Ziprasidone, Clinical guideline, Dosage, Switching, Adverse effect
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|